Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Oct 15, 2013; 4(5): 190-201
Published online Oct 15, 2013. doi: 10.4239/wjd.v4.i5.190
Published online Oct 15, 2013. doi: 10.4239/wjd.v4.i5.190
Effects of glucagon-like peptide-1 receptor agonists on renal function
Theodosios D Filippatos, Moses S Elisaf, Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece
Author contributions: Filippatos TD wrote the mini review, Elisaf MS edited and supervised the manuscript.
Correspondence to: Moses S Elisaf MD, FRSH, FASA, FISA, Professor, Department of Internal Medicine, School of Medicine, University of Ioannina, Staurou Niarchou Avenue, 45110 Ioannina, Greece. egepi@cc.uoi.gr
Telephone: +30-26510-07509 Fax: +30-26510-07016
Received: June 20, 2013
Revised: July 25, 2013
Accepted: August 16, 2013
Published online: October 15, 2013
Processing time: 118 Days and 9.5 Hours
Revised: July 25, 2013
Accepted: August 16, 2013
Published online: October 15, 2013
Processing time: 118 Days and 9.5 Hours
Core Tip
Core tip: Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus. A number of case reports show an association of GLP-1 receptor agonists, mainly exenatide, with the development of acute kidney injury. Exenatide is eliminated by renal mechanisms, but liraglutide is not eliminated by renal or hepatic mechanisms. GLP-1 receptor agonists exert protective role in animal models of diabetic nephropathy. The effects of these drugs may represent new ways to improve or even prevent diabetic nephropathy, but their exact mechanism of action need to be elucidated.